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Sir,
We read with some concern in the 13 October issue of your
journal the report of the outcome of the phase II study of Novello
et al (2009) on continuous daily sunitinib dosing in patients
previously treated with platinum-based chemotherapy for
advanced non-small-cell lung cancer. The trial suggests the
potential clinical benefit of this multitargeted tyrosine kinase
inhibitor in terms of progression arrest and shrinkage of target
lesions on fashionable waterfall plots. This showed one objective
partial response among 47 patients (2.1%) treated with a
continuous dosing of sunitinib. The interpretation of the efficacy
signal generated by this trial is hampered by the non-randomised,
non-controlled design of the study. The objective response rate did
not meet the pre-defined criterion required to reject the null
hypothesis, as at least five objective responses would have been
required for a positive outcome of the trial.
A considerable number of patients required dose and
schedule modifications. Globally, one out of four patients
(25%) discontinued treatment due to adverse events, including
four who stopped treatment during cycle 1 for side effects, once
again illustrating that multi-targeted tyrosine kinase inhibitors
should not be considered as an easy-to-administer, convenient
alternative to classical chemotherapy, especially not in a pre-
treated, often-elderly cohort of patients with highly refractory solid
tumours.
The assessment of safety was defined as a secondary end point
in this trial, but the type and frequency of laboratory tests for
biochemical evaluation of safety performed during the conduct of
the trial were not specified by the authors. We note with surprise
that patients participating in the study were not routinely screened
either for sunitinib-induced thyroid dysfunction or for cardiac
toxicity. There is no mention of routine thyroid or cardiac function
assessment during sunitinib treatment. In contrast to this,
hypothyroidism, first reported by Desai et al (2005), is a well-
known adverse side effect of sunitinib (Wolter et al, 2008a; Torino
et al, 2009). Remarkably, the authors report symptoms that are
possibly attributable to hypothyroidism in a large proportion of
their patients, including a 59.6% incidence of treatment-emergent
fatigue (17% of the cases that were categorised as grade 3/4 events),
but we could not find any information as to whether this was
related to thyroid dysfunction. This is a significant issue because
such symptoms might be due to sunitinib-induced hypothyroidism
and could therefore be reversible with thyroid hormone replace-
ment. Secondly, fatigue can also be related to cardiac failure, which
also has recently been reported as an important side effect of
sunitinib (Chu et al, 2007; Schmidinger et al, 2008; Telli et al, 2008;
DiLorenzo et al, 2009). Unfortunately, detailed information on
cardiac toxicity is also lacking, but the authors reported that at
least one patient died because of treatment-related congestive
heart failure.
According to a growing number of publications, if systematically
assessed by thyroid hormone determination, thyroid dysfunction
is seen in 30–60% of patients treated with sunitinib. In some cases
thyroid damage can even be irreversible, leading to the need for
long-term thyroid hormone replacement therapy (Wolter et al,
2008a; Torino et al, 2009; Rogiers et al, 2010), which, however,
should be carefully individualised (Garfield et al, 2007) in light of
the evidence that L-thyroxine has been shown to be a growth factor
in solid cancers acting via a non-genomic mechanism (i.e., through
the av beta 3 integrin receptor to activate tumour cell proliferation;
Lin et al, 2009). The determination of TSH levels in all patients
treated with sunitinib at baseline and during treatment, both
within and outside of clinical trials, is recommended by most
experts in the field (Kollmansberger et al, 2007; Bhojani et al,
2008). Recently, we have proposed an algorithm in this journal to
deal with this problem in daily clinical practice (Wolter et al,
2008a). Indeed, Hellevik et al (2009) have reported that in a large
prospective population (n¼30000) study of blood thyroid
hormone levels in individuals without a prior diagnosis of cancer,
a low TSH level was associated with an increased risk for
developing lung and prostate cancer – a risk factor that increases
with time.
Furthermore, there are preliminary data showing that thyroid
dysfunction under sunitinib treatment might be a surrogate
marker for clinical outcome (Wolter et al, 2008b). In a prospective
study of sunitinib-induced thyroid dysfunction in patients with
advanced renal cell carcinoma, the median progression-free
survival of patients with thyroid abnormalities was 10.3 months,
while for those without the abnormalities it was 3.6 months
(P¼0.047, log rank test). In addition, the group with thyroid
dysfunction had a median overall survival of 18.2 months
compared with 6.6 months in the euthyroid group (P¼0.13)
(Wolter et al, 2008b). To further explore thyroid dysfunction as a
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might have been important in the above-mentioned study.
In summary, we cannot conclude that the secondary end point
of the present study, namely, to assess the safety of sunitinib in this
patient population, was entirely met, as at least two important
and well-known side effects were not routinely assessed.
We recommend that the safety assessment in patients treated with
sunitinib and other tyrosine kinase inhibitors should always
include thyroid and cardiac function monitoring to avoid under-
reporting of adverse events, to adequately manage potentially
reversible side effects and to help identify off-target drug effects as
a possible surrogate marker for efficacy.
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